• Zanubrutinib - FDA Approval, Efficacy & Safety Profile in CLL - Discussion with Dr. Shadman

  • May 23 2024
  • Length: 22 mins
  • Podcast

Zanubrutinib - FDA Approval, Efficacy & Safety Profile in CLL - Discussion with Dr. Shadman By cover art

Zanubrutinib - FDA Approval, Efficacy & Safety Profile in CLL - Discussion with Dr. Shadman

Listen for free

View show details

  • Summary

  • Join Rahul and Rohit Gosain, the Oncology Brothers, in this insightful podcast episode where they discuss the latest advancements in hematology and oncology. In this episode, they are joined by Dr. Mazyar Shadman from Fred Hutch Cancer Center to delve into the Sequoia and Alpine trials that led to the approval of Zanubrutinib in CLL.

    Key Points Discussed:

    · The Sequoia trial focused on Zanubrutinib in first-line CLL treatment, showcasing its superiority over traditional chemotherapy.

    · The Alpine study compared Zanubrutinib to Ibrutinib in relapsed/refractory settings, demonstrating Zanubrutinib's efficacy and safety profile.

    · Acalabrutinib and Zanubrutinib were indirectly compared in a post-analysis, shedding light on their differences.

    · Dr. Shadman provides insights on managing common side effects of Zanubrutinib, highlighting its improved tolerability.

    Tune in to this episode for a comprehensive discussion on Zanubrutinib in CLL, including trial outcomes, comparisons, and practical considerations for patient care. Stay informed with the Oncology Brothers as they navigate the evolving landscape of oncology treatments

    Show more Show less
activate_primeday_promo_in_buybox_DT
Physical Illness & Disease Hygiene & Healthy Living
Show more Show less

What listeners say about Zanubrutinib - FDA Approval, Efficacy & Safety Profile in CLL - Discussion with Dr. Shadman

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available